Symbol:
Akr7a3
Name:
aldo-keto reductase family 7 member A3
RGD ID:
628635
Description:
Enables aldo-keto reductase (NADPH) activity. Involved in aflatoxin catabolic process. Predicted to be located in Golgi apparatus and cytosol. Predicted to be active in cytoplasm. Orthologous to several human genes including AKR7A3 (aldo-keto reductase family 7 member A3); INTERACTS WITH 1,3-dinitrobenzene; 1-nitropropane; 17alpha-ethynylestradiol.
Type:
protein-coding
RefSeq Status:
PROVISIONAL
Previously known as:
Afar; AFB1-AR; aflatoxin B1 aldehyde reductase; aflatoxin B1 aldehyde reductase member 1; aflatoxin B1 aldehyde reductase member 3; Akr7a1; aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase); rAFAR1
RGD Orthologs
Alliance Orthologs
More Info
more info ...
More Info
Latest Assembly:
GRCr8 - GRCr8 Assembly
Position:
Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl GRCr8 5 156,876,721 - 156,884,599 (+) NCBI GRCr8 mRatBN7.2 5 151,590,968 - 151,601,394 (+) NCBI mRatBN7.2 mRatBN7.2 mRatBN7.2 Ensembl 5 151,584,479 - 151,601,394 (+) Ensembl mRatBN7.2 Ensembl UTH_Rnor_SHR_Utx 5 154,292,151 - 154,300,047 (+) NCBI Rnor_SHR UTH_Rnor_SHR_Utx UTH_Rnor_SHRSP_BbbUtx_1.0 5 156,066,511 - 156,074,407 (+) NCBI Rnor_SHRSP UTH_Rnor_SHRSP_BbbUtx_1.0 UTH_Rnor_WKY_Bbb_1.0 5 156,047,478 - 156,055,349 (+) NCBI Rnor_WKY UTH_Rnor_WKY_Bbb_1.0 Rnor_6.0 5 157,801,120 - 157,813,756 (+) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 5 157,801,163 - 157,813,756 (+) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 5 161,540,977 - 161,553,468 (+) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 5 158,139,986 - 158,147,516 (+) NCBI RGSC3.4 RGSC_v3.4 rn4 RGSC3.4 RGSC_v3.1 5 158,150,024 - 158,157,553 (+) NCBI Celera 5 149,973,124 - 149,980,999 (+) NCBI Celera Cytogenetic Map 5 q36 NCBI
JBrowse:
View Region in Genome Browser (JBrowse)
Model
Only show annotations with direct experimental evidence (0 objects hidden)
Akr7a3 Rat 1,3-dinitrobenzene increases expression EXP 6480464 3-dinitrobenzene results in increased expression of AKR7A3 mRNA CTD PMID:21983209 Akr7a3 Rat 1-nitropropane decreases expression EXP 6480464 1-nitropropane results in decreased expression of AKR7A3 mRNA CTD PMID:17070881 Akr7a3 Rat 17alpha-ethynylestradiol increases expression EXP 6480464 Ethinyl Estradiol results in increased expression of AKR7A3 mRNA CTD PMID:17108234 Akr7a3 Rat 17beta-estradiol decreases expression EXP 6480464 Estradiol results in decreased expression of AKR7A3 mRNA CTD PMID:32145629 Akr7a3 Rat 2,3,7,8-tetrachlorodibenzodioxine decreases expression EXP 6480464 Tetrachlorodibenzodioxin results in decreased expression of AKR7A3 mRNA CTD PMID:21215274 Akr7a3 Rat 2,3,7,8-tetrachlorodibenzodioxine increases expression EXP 6480464 Tetrachlorodibenzodioxin results in increased expression of AKR7A3 mRNA CTD PMID:16054898 more ... Akr7a3 Rat 2,4,6-trinitrotoluene affects expression EXP 6480464 Trinitrotoluene affects the expression of AKR7A3 mRNA CTD PMID:21346803 Akr7a3 Rat 2,4-diaminotoluene increases expression EXP 6480464 2 and 4-diaminotoluene results in increased expression of AKR7A3 mRNA CTD PMID:17070881 Akr7a3 Rat 2,4-dinitrotoluene affects expression EXP 6480464 2 and 4-dinitrotoluene affects the expression of AKR7A3 mRNA CTD PMID:21346803 Akr7a3 Rat 2,6-di-tert-butyl-4-methylphenol increases expression EXP 6480464 Butylated Hydroxytoluene results in increased expression of AKR7A3 protein CTD PMID:8198522 Akr7a3 Rat 2,6-di-tert-butyl-4-methylphenol increases activity EXP 6480464 Butylated Hydroxytoluene results in increased activity of AKR7A3 protein CTD PMID:9328168 Akr7a3 Rat 2,6-diaminotoluene decreases expression EXP 6480464 2 and 6-diaminotoluene results in decreased expression of AKR7A3 mRNA CTD PMID:17070881 Akr7a3 Rat 2,6-dinitrotoluene affects expression EXP 6480464 2 and 6-dinitrotoluene affects the expression of AKR7A3 mRNA CTD PMID:21346803 Akr7a3 Rat 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one increases expression EXP 6480464 Praziquantel results in increased expression of AKR7A3 mRNA CTD PMID:21813463 Akr7a3 Rat 2-acetamidofluorene increases expression EXP 6480464 2-Acetylaminofluorene results in increased expression of AKR7A3 mRNA CTD PMID:17070881 Akr7a3 Rat 2-amino-4,6-dinitrotoluene affects expression EXP 6480464 2-amino-4 and 6-dinitrotoluene affects the expression of AKR7A3 mRNA CTD PMID:21346803 Akr7a3 Rat 2-nitro-p-phenylenediamine increases expression EXP 6480464 2-nitro-4-phenylenediamine results in increased expression of AKR7A3 mRNA CTD PMID:17070881 Akr7a3 Rat 2-nitrofluorene increases expression EXP 6480464 2-nitrofluorene results in increased expression of AKR7A3 mRNA CTD PMID:14600272 more ... Akr7a3 Rat 2-nitropropane increases expression EXP 6480464 2-nitropropane results in increased expression of AKR7A3 mRNA CTD PMID:17070881 Akr7a3 Rat 2-palmitoylglycerol increases expression ISO AKR7A3 (Homo sapiens) 6480464 2-palmitoylglycerol results in increased expression of AKR7A3 mRNA CTD PMID:37199045 Akr7a3 Rat 3,3',4,4',5-pentachlorobiphenyl increases expression EXP 6480464 3 more ... CTD PMID:20959002 Akr7a3 Rat 3-chloropropane-1,2-diol increases expression EXP 6480464 alpha-Chlorohydrin results in increased expression of AKR7A3 protein CTD PMID:34915118 Akr7a3 Rat 3H-1,2-dithiole-3-thione increases expression EXP 6480464 1 more ... CTD PMID:19162173 more ... Akr7a3 Rat 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one increases expression EXP 6480464 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of AKR7A3 mRNA CTD PMID:14600272 and PMID:23052194 Akr7a3 Rat 4-acetylaminofluorene increases expression EXP 6480464 4-acetylaminofluorene results in increased expression of AKR7A3 mRNA CTD PMID:17070881 Akr7a3 Rat 4-amino-2,6-dinitrotoluene affects expression EXP 6480464 4-amino-2 and 6-dinitrotoluene affects the expression of AKR7A3 mRNA CTD PMID:21346803 Akr7a3 Rat 4-nitro-1,2-phenylenediamine increases expression EXP 6480464 1 and 2-diamino-4-nitrobenzene results in increased expression of AKR7A3 mRNA CTD PMID:17070881 Akr7a3 Rat 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole multiple interactions EXP 6480464 [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA CTD PMID:22687989 Akr7a3 Rat 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole affects expression EXP 6480464 Omeprazole affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat 6-propyl-2-thiouracil affects expression EXP 6480464 Propylthiouracil affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat 6-propyl-2-thiouracil increases expression EXP 6480464 Propylthiouracil results in increased expression of AKR7A3 mRNA CTD PMID:30047161 Akr7a3 Rat 6-propyl-2-thiouracil decreases expression EXP 6480464 Propylthiouracil results in decreased expression of AKR7A3 mRNA CTD PMID:24780913 and PMID:25825206 Akr7a3 Rat 9,10-phenanthroquinone increases reduction EXP 6480464 AKR7A3 protein results in increased reduction of 9 and 10-phenanthrenequinone CTD PMID:19168568 Akr7a3 Rat 9,10-phenanthroquinone multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 AKR7A3 protein results in increased reduction of and affects the activity of 9 and 10-phenanthrenequinone CTD PMID:21910479 Akr7a3 Rat acetamide increases expression EXP 6480464 acetamide results in increased expression of AKR7A3 mRNA CTD PMID:31881176 Akr7a3 Rat acrolein affects metabolic processing EXP 6480464 AKR7A3 protein affects the metabolism of Acrolein CTD PMID:15019089 Akr7a3 Rat acrolein decreases response to substance EXP 6480464 AKR7A3 protein results in decreased susceptibility to Acrolein CTD PMID:15019089 Akr7a3 Rat aflatoxin B1 affects expression ISO AKR7A3 (Homo sapiens) 6480464 Aflatoxin B1 affects the expression of AKR7A3 protein CTD PMID:20106945 Akr7a3 Rat aflatoxin B1 decreases expression ISO AKR7A3 (Homo sapiens) 6480464 Aflatoxin B1 results in decreased expression of AKR7A3 mRNA CTD PMID:27153756 Akr7a3 Rat aflatoxin B1 increases expression EXP 6480464 Aflatoxin B1 results in increased expression of AKR7A3 mRNA CTD PMID:14600272 more ... Akr7a3 Rat aflatoxin B1 decreases response to substance EXP 6480464 AKR7A3 protein results in decreased susceptibility to Aflatoxin B1 CTD PMID:8395332 Akr7a3 Rat aflatoxin B1 increases reduction EXP 6480464 AKR7A3 protein results in increased reduction of Aflatoxin B1 metabolite CTD PMID:19168568 Akr7a3 Rat aflatoxin B1 affects metabolic processing EXP 6480464 AKR7A3 protein affects the metabolism of Aflatoxin B1 CTD PMID:8395332 Akr7a3 Rat amiodarone affects expression EXP 6480464 Amiodarone affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat ammonium chloride affects expression EXP 6480464 Ammonium Chloride affects the expression of AKR7A3 mRNA CTD PMID:16483693 Akr7a3 Rat antirheumatic drug increases expression ISO AKR7A3 (Homo sapiens) 6480464 Antirheumatic Agents results in increased expression of AKR7A3 mRNA CTD PMID:24449571 Akr7a3 Rat aristolochic acid A multiple interactions EXP 6480464 [aristolochic acid I co-treated with aristolochic acid II] results in increased expression of AKR7A3 mRNA CTD PMID:23912714 Akr7a3 Rat aristolochic acid A increases expression ISO AKR7A3 (Homo sapiens) 6480464 aristolochic acid I results in increased expression of AKR7A3 mRNA CTD PMID:33212167 Akr7a3 Rat Aroclor 1254 increases expression EXP 6480464 Chlorodiphenyl (54% Chlorine) results in increased expression of AKR7A3 mRNA CTD PMID:18178546 Akr7a3 Rat arsenous acid multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to AKR7A3 protein] CTD PMID:26598702 Akr7a3 Rat atazanavir sulfate multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 Akr7a3 Rat atazanavir sulfate decreases expression ISO AKR7A3 (Homo sapiens) 6480464 Atazanavir Sulfate results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 Akr7a3 Rat atrazine decreases expression EXP 6480464 Atrazine results in decreased expression of AKR7A3 mRNA CTD PMID:36841081 Akr7a3 Rat benzbromarone affects expression EXP 6480464 Benzbromarone affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat benzene affects expression EXP 6480464 Benzene affects the expression of AKR7A3 mRNA CTD PMID:15878777 Akr7a3 Rat benzo[a]pyrene decreases expression ISO AKR7A3 (Homo sapiens) 6480464 Benzo(a)pyrene results in decreased expression of AKR7A3 mRNA CTD PMID:20106945 and PMID:32234424 Akr7a3 Rat benzo[a]pyrene affects methylation ISO AKR7A3 (Homo sapiens) 6480464 Benzo(a)pyrene affects the methylation of AKR7A3 promoter CTD PMID:27901495 Akr7a3 Rat benzo[a]pyrene-7,8-dione multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of benzo(a)pyrene-7 and 8-dione CTD PMID:21910479 Akr7a3 Rat beta-naphthoflavone multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of AKR7A3 mRNA CTD PMID:18164116 Akr7a3 Rat beta-naphthoflavone increases expression EXP 6480464 beta-Naphthoflavone results in increased expression of AKR7A3 mRNA CTD PMID:22687991 Akr7a3 Rat bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of AKR7A3 mRNA CTD PMID:25181051 and PMID:30903817 Akr7a3 Rat bisphenol A decreases expression ISO AKR7A3 (Homo sapiens) 6480464 bisphenol A results in decreased expression of AKR7A3 mRNA CTD PMID:31715268 Akr7a3 Rat bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of AKR7A3 mRNA CTD PMID:30816183 more ... Akr7a3 Rat bromobenzene increases expression EXP 6480464 bromobenzene results in increased expression of AKR7A3 mRNA CTD PMID:12628495 more ... Akr7a3 Rat buspirone decreases expression EXP 6480464 Buspirone results in decreased expression of AKR7A3 mRNA CTD PMID:24136188 Akr7a3 Rat butylated hydroxyanisole increases expression EXP 6480464 Butylated Hydroxyanisole results in increased expression of AKR7A3 protein CTD PMID:8198522 Akr7a3 Rat cadmium atom multiple interactions EXP 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of AKR7A3 mRNA CTD PMID:29298499 Akr7a3 Rat cadmium dichloride decreases expression EXP 6480464 Cadmium Chloride results in decreased expression of AKR7A3 mRNA CTD PMID:25993096 Akr7a3 Rat cadmium dichloride multiple interactions EXP 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of AKR7A3 mRNA CTD PMID:29298499 Akr7a3 Rat cafestol multiple interactions EXP 6480464 [cafestol co-treated with kahweol] inhibits the reaction [ochratoxin A results in decreased expression of AKR7A3 protein] CTD PMID:17110534 Akr7a3 Rat capsaicin multiple interactions EXP 6480464 Capsaicin inhibits the reaction [Dietary Fats results in decreased expression of AKR7A3 protein] CTD PMID:20359164 Akr7a3 Rat carbamazepine increases expression EXP 6480464 Carbamazepine results in increased expression of AKR7A3 mRNA CTD PMID:17381134 Akr7a3 Rat chenodeoxycholic acid decreases expression ISO AKR7A3 (Homo sapiens) 6480464 Chenodeoxycholic Acid results in decreased expression of AKR7A3 mRNA CTD PMID:27174168 Akr7a3 Rat chenodeoxycholic acid multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA more ... CTD PMID:32152650 and PMID:33819548 Akr7a3 Rat chloroform increases expression EXP 6480464 Chloroform results in increased expression of AKR7A3 mRNA CTD PMID:21813463 Akr7a3 Rat chlorohydrocarbon multiple interactions EXP 6480464 [Hydrocarbons more ... CTD PMID:30744511 Akr7a3 Rat cisplatin increases expression EXP 6480464 Cisplatin results in increased expression of AKR7A3 mRNA CTD PMID:18246545 more ... Akr7a3 Rat clofibrate increases expression EXP 6480464 Clofibrate results in increased expression of AKR7A3 mRNA CTD PMID:12011481 Akr7a3 Rat clofibrate affects expression EXP 6480464 Clofibrate affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat cobalt dichloride increases expression EXP 6480464 cobaltous chloride results in increased expression of AKR7A3 mRNA and cobaltous chloride results in increased expression of AKR7A3 protein CTD PMID:24386269 Akr7a3 Rat cocaine affects expression EXP 6480464 Cocaine affects the expression of AKR7A3 mRNA CTD PMID:20187946 Akr7a3 Rat copper(II) sulfate decreases expression ISO AKR7A3 (Homo sapiens) 6480464 Copper Sulfate results in decreased expression of AKR7A3 mRNA CTD PMID:19549813 Akr7a3 Rat coumarin increases expression EXP 6480464 coumarin results in increased expression of AKR7A3 mRNA CTD PMID:18480146 Akr7a3 Rat Cuprizon decreases expression EXP 6480464 Cuprizone results in decreased expression of AKR7A3 mRNA CTD PMID:26577399 and PMID:27523638 Akr7a3 Rat cyclosporin A decreases expression ISO AKR7A3 (Homo sapiens) 6480464 Cyclosporine results in decreased expression of AKR7A3 mRNA CTD PMID:20106945 and PMID:25562108 Akr7a3 Rat cyclosporin A multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 Akr7a3 Rat deoxycholic acid multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA more ... CTD PMID:32152650 and PMID:33819548 Akr7a3 Rat Diallyl sulfide increases expression EXP 6480464 allyl sulfide results in increased expression of AKR7A3 mRNA CTD PMID:19695238 Akr7a3 Rat diarsenic trioxide multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 Arsenic Trioxide inhibits the reaction [4-aminophenylarsenoxide binds to AKR7A3 protein] CTD PMID:26598702 Akr7a3 Rat dibutyl phthalate decreases expression EXP 6480464 Dibutyl Phthalate results in decreased expression of AKR7A3 mRNA CTD PMID:21266533 Akr7a3 Rat dichlorvos increases expression EXP 6480464 Dichlorvos results in increased expression of AKR7A3 mRNA CTD PMID:21813463 Akr7a3 Rat diuron increases expression EXP 6480464 Diuron results in increased expression of AKR7A3 mRNA CTD PMID:25152437 Akr7a3 Rat emodin decreases activity ISO AKR7A3 (Homo sapiens) 6480464 Emodin results in decreased activity of AKR7A3 protein CTD PMID:35065925 Akr7a3 Rat endosulfan increases expression EXP 6480464 Endosulfan results in increased expression of AKR7A3 mRNA CTD PMID:29391264 Akr7a3 Rat ethanol decreases expression ISO AKR7A3 (Homo sapiens) 6480464 Ethanol results in decreased expression of AKR7A3 protein CTD PMID:20621659 Akr7a3 Rat ethoxyquin increases expression EXP 6480464 Ethoxyquin results in increased expression of AKR7A3 mRNA and Ethoxyquin results in increased expression of AKR7A3 protein CTD PMID:19695238 more ... Akr7a3 Rat ethoxyquin increases activity EXP 6480464 Ethoxyquin results in increased activity of AKR7A3 protein CTD PMID:9328168 Akr7a3 Rat etofenprox multiple interactions EXP 6480464 [ethofenprox co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA CTD PMID:22467020 Akr7a3 Rat felbamate increases expression EXP 6480464 felbamate results in increased expression of AKR7A3 mRNA CTD PMID:17381134 Akr7a3 Rat finasteride increases expression EXP 6480464 Finasteride results in increased expression of AKR7A3 mRNA CTD PMID:24136188 Akr7a3 Rat fipronil increases expression EXP 6480464 fipronil results in increased expression of AKR7A3 mRNA CTD PMID:23962444 Akr7a3 Rat fluconazole increases expression EXP 6480464 Fluconazole results in increased expression of AKR7A3 mRNA CTD PMID:16643972 Akr7a3 Rat flutamide increases expression EXP 6480464 Flutamide results in increased expression of AKR7A3 mRNA CTD PMID:24136188 Akr7a3 Rat flutamide decreases expression EXP 6480464 Flutamide results in decreased expression of AKR7A3 mRNA CTD PMID:24793618 Akr7a3 Rat furan increases methylation EXP 6480464 furan results in increased methylation of AKR7A3 gene CTD PMID:22079235 Akr7a3 Rat furan increases expression EXP 6480464 furan results in increased expression of AKR7A3 mRNA CTD PMID:15120968 more ... Akr7a3 Rat gabapentin increases expression EXP 6480464 gabapentin results in increased expression of AKR7A3 mRNA CTD PMID:17381134 Akr7a3 Rat gamma-hexachlorocyclohexane increases expression EXP 6480464 Hexachlorocyclohexane results in increased expression of AKR7A3 mRNA CTD PMID:17785943 Akr7a3 Rat gemfibrozil affects expression EXP 6480464 Gemfibrozil affects the expression of AKR7A3 mRNA CTD PMID:12011481 Akr7a3 Rat gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of AKR7A3 protein CTD PMID:21081137 and PMID:22061828 Akr7a3 Rat gentamycin increases expression EXP 6480464 Gentamicins results in increased expression of AKR7A3 mRNA CTD PMID:33387578 Akr7a3 Rat glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of AKR7A3 mRNA CTD PMID:24136188 Akr7a3 Rat glutathione increases expression EXP 6480464 Glutathione deficiency results in increased expression of AKR7A3 mRNA CTD PMID:15345336 and PMID:20621112 Akr7a3 Rat glycochenodeoxycholic acid multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA more ... CTD PMID:32152650 and PMID:33819548 Akr7a3 Rat glycocholic acid multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA more ... CTD PMID:32152650 and PMID:33819548 Akr7a3 Rat glycodeoxycholic acid multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA more ... CTD PMID:32152650 and PMID:33819548 Akr7a3 Rat indole-3-methanol increases activity EXP 6480464 indole-3-carbinol results in increased activity of AKR7A3 protein CTD PMID:9328168 Akr7a3 Rat indole-3-methanol multiple interactions EXP 6480464 [indole-3-carbinol co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA CTD PMID:22129741 Akr7a3 Rat indole-3-methanol affects expression EXP 6480464 indole-3-carbinol affects the expression of AKR7A3 mRNA CTD PMID:21396975 Akr7a3 Rat kahweol multiple interactions EXP 6480464 [cafestol co-treated with kahweol] inhibits the reaction [ochratoxin A results in decreased expression of AKR7A3 protein] CTD PMID:17110534 Akr7a3 Rat L-ethionine affects expression EXP 6480464 Ethionine affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat lead diacetate increases expression EXP 6480464 lead acetate results in increased expression of AKR7A3 mRNA CTD PMID:22641619 Akr7a3 Rat melatonin multiple interactions EXP 6480464 Melatonin inhibits the reaction [[Diethylnitrosamine co-treated with oxfendazole] results in increased expression of AKR7A3 mRNA] CTD PMID:20033131 Akr7a3 Rat mercury atom multiple interactions EXP 6480464 [Mercuric Chloride results in increased abundance of Mercury] which results in increased expression of AKR7A3 mRNA and [Mercuric Chloride results in increased abundance of Mercury] which results in increased expression of AKR7A3 protein CTD PMID:29298499 Akr7a3 Rat mercury dichloride multiple interactions EXP 6480464 [Mercuric Chloride results in increased abundance of Mercury] which results in increased expression of AKR7A3 mRNA and [Mercuric Chloride results in increased abundance of Mercury] which results in increased expression of AKR7A3 protein CTD PMID:29298499 Akr7a3 Rat mercury(0) multiple interactions EXP 6480464 [Mercuric Chloride results in increased abundance of Mercury] which results in increased expression of AKR7A3 mRNA and [Mercuric Chloride results in increased abundance of Mercury] which results in increased expression of AKR7A3 protein CTD PMID:29298499 Akr7a3 Rat methapyrilene increases expression EXP 6480464 Methapyrilene results in increased expression of AKR7A3 mRNA CTD PMID:15120968 more ... Akr7a3 Rat methimazole increases expression EXP 6480464 Methimazole results in increased expression of AKR7A3 mRNA CTD PMID:30047161 Akr7a3 Rat methylmercury chloride multiple interactions EXP 6480464 [Hydrocarbons more ... CTD PMID:30744511 Akr7a3 Rat N-nitrosodiethylamine multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of AKR7A3 mRNA more ... CTD PMID:18164116 more ... Akr7a3 Rat N-nitrosodiethylamine increases expression EXP 6480464 Diethylnitrosamine results in increased expression of AKR7A3 mRNA CTD PMID:19638242 and PMID:21813463 Akr7a3 Rat N-nitrosodiethylamine decreases expression EXP 6480464 Diethylnitrosamine results in decreased expression of AKR7A3 mRNA CTD PMID:11323195 Akr7a3 Rat N-nitrosodimethylamine increases expression EXP 6480464 Dimethylnitrosamine results in increased expression of AKR7A3 mRNA CTD PMID:14600272 Akr7a3 Rat N-nitrosomorpholine increases expression EXP 6480464 N-nitrosomorpholine results in increased expression of AKR7A3 mRNA and N-nitrosomorpholine results in increased expression of AKR7A3 protein CTD PMID:19716841 Akr7a3 Rat NADP zwitterion multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone more ... CTD PMID:21910479 Akr7a3 Rat NADP(+) multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [AKR7A3 protein co-treated with NADP] results in increased reduction of and affects the activity of 4-hydroxyequilenin-o-quinone more ... CTD PMID:21910479 Akr7a3 Rat naphthalene increases expression EXP 6480464 naphthalene analog results in increased expression of AKR7A3 mRNA CTD PMID:24976557 Akr7a3 Rat naphthalenes multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 AKR7A3 protein results in increased reduction of and affects the activity of Naphthalenes CTD PMID:21910479 Akr7a3 Rat nefazodone increases expression EXP 6480464 nefazodone results in increased expression of AKR7A3 mRNA CTD PMID:24136188 Akr7a3 Rat nefazodone decreases expression ISO AKR7A3 (Homo sapiens) 6480464 nefazodone results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 Akr7a3 Rat nefazodone multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA CTD PMID:32152650 Akr7a3 Rat nimesulide increases expression EXP 6480464 nimesulide results in increased expression of AKR7A3 mRNA CTD PMID:24136188 Akr7a3 Rat O-methyleugenol decreases expression ISO AKR7A3 (Homo sapiens) 6480464 methyleugenol results in decreased expression of AKR7A3 mRNA CTD PMID:32234424 Akr7a3 Rat ochratoxin A multiple interactions EXP 6480464 [cafestol co-treated with kahweol] inhibits the reaction [ochratoxin A results in decreased expression of AKR7A3 protein] CTD PMID:17110534 Akr7a3 Rat ochratoxin A decreases expression EXP 6480464 ochratoxin A results in decreased expression of AKR7A3 mRNA and ochratoxin A results in decreased expression of AKR7A3 protein CTD PMID:16251485 and PMID:17110534 Akr7a3 Rat oltipraz increases activity EXP 6480464 oltipraz results in increased activity of AKR7A3 protein CTD PMID:9328168 Akr7a3 Rat omeprazole affects expression EXP 6480464 Omeprazole affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat omeprazole multiple interactions EXP 6480464 [Omeprazole co-treated with Diethylnitrosamine] results in increased expression of AKR7A3 mRNA CTD PMID:22687989 Akr7a3 Rat orphenadrine affects expression EXP 6480464 Orphenadrine affects the expression of AKR7A3 mRNA CTD PMID:23665939 Akr7a3 Rat oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of AKR7A3 mRNA CTD PMID:25729387 Akr7a3 Rat oxfendazole multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of AKR7A3 mRNA more ... CTD PMID:18754104 and PMID:20033131 Akr7a3 Rat p-toluidine increases expression EXP 6480464 4-toluidine results in increased expression of AKR7A3 mRNA CTD PMID:27638505 Akr7a3 Rat paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of AKR7A3 mRNA CTD PMID:15120968 more ... Akr7a3 Rat paracetamol multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA CTD PMID:33819548 Akr7a3 Rat perfluorooctane-1-sulfonic acid increases expression EXP 6480464 perfluorooctane sulfonic acid results in increased expression of AKR7A3 mRNA CTD PMID:19162173 Akr7a3 Rat phenethyl isothiocyanate increases expression EXP 6480464 phenethyl isothiocyanate results in increased expression of AKR7A3 mRNA CTD PMID:17616710 Akr7a3 Rat phenethyl isothiocyanate increases activity EXP 6480464 phenethyl isothiocyanate results in increased activity of AKR7A3 protein CTD PMID:9328168 Akr7a3 Rat phenobarbital increases expression EXP 6480464 Phenobarbital results in increased expression of AKR7A3 mRNA CTD PMID:12011481 more ... Akr7a3 Rat phenytoin decreases expression EXP 6480464 Phenytoin results in decreased expression of AKR7A3 mRNA CTD PMID:17381134 Akr7a3 Rat phenytoin increases expression EXP 6480464 Phenytoin results in increased expression of AKR7A3 mRNA CTD PMID:17381134 Akr7a3 Rat piperonyl butoxide increases expression EXP 6480464 Piperonyl Butoxide results in increased expression of AKR7A3 mRNA CTD PMID:18544911 and PMID:22484513 Akr7a3 Rat piperonyl butoxide multiple interactions EXP 6480464 Triterpenes promotes the reaction [Piperonyl Butoxide results in increased expression of AKR7A3 mRNA] CTD PMID:18544911 Akr7a3 Rat pirinixic acid decreases expression EXP 6480464 pirinixic acid results in decreased expression of AKR7A3 mRNA CTD PMID:19162173 Akr7a3 Rat pirinixic acid increases expression EXP 6480464 pirinixic acid results in increased expression of AKR7A3 mRNA CTD PMID:12011481 Akr7a3 Rat pirinixic acid affects expression EXP 6480464 pirinixic acid affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat pregnenolone 16alpha-carbonitrile increases expression EXP 6480464 Pregnenolone Carbonitrile results in increased expression of AKR7A3 mRNA CTD PMID:19162173 and PMID:30047161 Akr7a3 Rat propiconazole increases expression EXP 6480464 propiconazole results in increased expression of AKR7A3 mRNA CTD PMID:16643972 Akr7a3 Rat pyrazinecarboxamide increases expression EXP 6480464 Pyrazinamide results in increased expression of AKR7A3 mRNA CTD PMID:22431067 Akr7a3 Rat quercetin affects expression EXP 6480464 Quercetin affects the expression of AKR7A3 mRNA CTD PMID:18178720 Akr7a3 Rat quercetin increases expression EXP 6480464 Quercetin results in increased expression of AKR7A3 mRNA CTD PMID:19191009 Akr7a3 Rat quercetin 3-O-beta-D-glucofuranoside multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of AKR7A3 mRNA CTD PMID:20033131 Akr7a3 Rat quercetin 3-O-beta-D-glucopyranoside multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with oxfendazole co-treated with isoquercitrin] results in increased expression of AKR7A3 mRNA CTD PMID:20033131 Akr7a3 Rat sinigrin increases activity EXP 6480464 sinigrin results in increased activity of AKR7A3 protein CTD PMID:9328168 Akr7a3 Rat sodium arsenite increases expression ISO AKR7A3 (Homo sapiens) 6480464 sodium arsenite results in increased expression of AKR7A3 mRNA CTD PMID:34032870 Akr7a3 Rat sodium dichromate increases expression EXP 6480464 sodium bichromate results in increased expression of AKR7A3 mRNA CTD PMID:25993096 Akr7a3 Rat streptozocin increases expression EXP 6480464 Streptozocin results in increased expression of AKR7A3 mRNA CTD PMID:25905778 Akr7a3 Rat succinic semialdehyde affects metabolic processing EXP 6480464 AKR7A3 protein affects the metabolism of succinic semialdehyde CTD PMID:15019089 Akr7a3 Rat Sunset Yellow FCF multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA CTD PMID:33819548 Akr7a3 Rat tartrazine multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA CTD PMID:33819548 Akr7a3 Rat tetrachloromethane increases expression EXP 6480464 Carbon Tetrachloride results in increased expression of AKR7A3 mRNA CTD PMID:31150632 Akr7a3 Rat thioacetamide affects expression EXP 6480464 Thioacetamide affects the expression of AKR7A3 mRNA CTD PMID:19483382 Akr7a3 Rat thioacetamide multiple interactions EXP 6480464 [Diethylnitrosamine co-treated with Thioacetamide] results in increased expression of AKR7A3 mRNA CTD PMID:28943392 Akr7a3 Rat thioacetamide increases expression EXP 6480464 Thioacetamide results in increased expression of AKR7A3 mRNA CTD PMID:23411599 and PMID:34492290 Akr7a3 Rat toluene affects expression EXP 6480464 Toluene affects the expression of AKR7A3 mRNA CTD PMID:18653662 Akr7a3 Rat topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of AKR7A3 mRNA CTD PMID:25729387 Akr7a3 Rat topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of AKR7A3 mRNA CTD PMID:25729387 Akr7a3 Rat triadimefon increases expression EXP 6480464 triadimefon results in increased expression of AKR7A3 mRNA CTD PMID:16643972 Akr7a3 Rat trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of AKR7A3 mRNA CTD PMID:19448997 and PMID:33387578 Akr7a3 Rat triclosan multiple interactions ISO AKR7A3 (Homo sapiens) 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA CTD PMID:33819548 Akr7a3 Rat triphenyl phosphate increases expression EXP 6480464 triphenyl phosphate results in increased expression of AKR7A3 mRNA CTD PMID:30589522 Akr7a3 Rat triphenyl phosphate affects expression ISO AKR7A3 (Homo sapiens) 6480464 triphenyl phosphate affects the expression of AKR7A3 mRNA CTD PMID:37042841 Akr7a3 Rat trovafloxacin decreases expression EXP 6480464 trovafloxacin results in decreased expression of AKR7A3 mRNA CTD PMID:24136188 Akr7a3 Rat umbelliferone increases expression ISO AKR7A3 (Homo sapiens) 6480464 7-hydroxycoumarin results in increased expression of AKR7A3 mRNA CTD PMID:28263721 Akr7a3 Rat valdecoxib increases expression EXP 6480464 valdecoxib results in increased expression of AKR7A3 mRNA CTD PMID:24136188 Akr7a3 Rat valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of AKR7A3 mRNA CTD PMID:17381134 and PMID:23665938
1,3-dinitrobenzene (EXP) 1-nitropropane (EXP) 17alpha-ethynylestradiol (EXP) 17beta-estradiol (EXP) 2,3,7,8-tetrachlorodibenzodioxine (EXP) 2,4,6-trinitrotoluene (EXP) 2,4-diaminotoluene (EXP) 2,4-dinitrotoluene (EXP) 2,6-di-tert-butyl-4-methylphenol (EXP) 2,6-diaminotoluene (EXP) 2,6-dinitrotoluene (EXP) 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one (EXP) 2-acetamidofluorene (EXP) 2-amino-4,6-dinitrotoluene (EXP) 2-nitro-p-phenylenediamine (EXP) 2-nitrofluorene (EXP) 2-nitropropane (EXP) 2-palmitoylglycerol (ISO) 3,3',4,4',5-pentachlorobiphenyl (EXP) 3-chloropropane-1,2-diol (EXP) 3H-1,2-dithiole-3-thione (EXP) 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one (EXP) 4-acetylaminofluorene (EXP) 4-amino-2,6-dinitrotoluene (EXP) 4-nitro-1,2-phenylenediamine (EXP) 5-methoxy-2-\{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl\}-1H-benzimidazole (EXP) 6-propyl-2-thiouracil (EXP) 9,10-phenanthroquinone (EXP,ISO) acetamide (EXP) acrolein (EXP) aflatoxin B1 (EXP,ISO) amiodarone (EXP) ammonium chloride (EXP) antirheumatic drug (ISO) aristolochic acid A (EXP,ISO) Aroclor 1254 (EXP) arsenous acid (ISO) atazanavir sulfate (ISO) atrazine (EXP) benzbromarone (EXP) benzene (EXP) benzo[a]pyrene (ISO) benzo[a]pyrene-7,8-dione (ISO) beta-naphthoflavone (EXP) bisphenol A (EXP,ISO) bromobenzene (EXP) buspirone (EXP) butylated hydroxyanisole (EXP) cadmium atom (EXP) cadmium dichloride (EXP) cafestol (EXP) capsaicin (EXP) carbamazepine (EXP) chenodeoxycholic acid (ISO) chloroform (EXP) chlorohydrocarbon (EXP) cisplatin (EXP) clofibrate (EXP) cobalt dichloride (EXP) cocaine (EXP) copper(II) sulfate (ISO) coumarin (EXP) Cuprizon (EXP) cyclosporin A (ISO) deoxycholic acid (ISO) Diallyl sulfide (EXP) diarsenic trioxide (ISO) dibutyl phthalate (EXP) dichlorvos (EXP) diuron (EXP) emodin (ISO) endosulfan (EXP) ethanol (ISO) ethoxyquin (EXP) etofenprox (EXP) felbamate (EXP) finasteride (EXP) fipronil (EXP) fluconazole (EXP) flutamide (EXP) furan (EXP) gabapentin (EXP) gamma-hexachlorocyclohexane (EXP) gemfibrozil (EXP) gentamycin (EXP) glafenine (EXP) glutathione (EXP) glycochenodeoxycholic acid (ISO) glycocholic acid (ISO) glycodeoxycholic acid (ISO) indole-3-methanol (EXP) kahweol (EXP) L-ethionine (EXP) lead diacetate (EXP) melatonin (EXP) mercury atom (EXP) mercury dichloride (EXP) mercury(0) (EXP) methapyrilene (EXP) methimazole (EXP) methylmercury chloride (EXP) N-nitrosodiethylamine (EXP) N-nitrosodimethylamine (EXP) N-nitrosomorpholine (EXP) NADP zwitterion (ISO) NADP(+) (ISO) naphthalene (EXP) naphthalenes (ISO) nefazodone (EXP,ISO) nimesulide (EXP) O-methyleugenol (ISO) ochratoxin A (EXP) oltipraz (EXP) omeprazole (EXP) orphenadrine (EXP) oxaliplatin (EXP) oxfendazole (EXP) p-toluidine (EXP) paracetamol (EXP,ISO) perfluorooctane-1-sulfonic acid (EXP) phenethyl isothiocyanate (EXP) phenobarbital (EXP) phenytoin (EXP) piperonyl butoxide (EXP) pirinixic acid (EXP) pregnenolone 16alpha-carbonitrile (EXP) propiconazole (EXP) pyrazinecarboxamide (EXP) quercetin (EXP) quercetin 3-O-beta-D-glucofuranoside (EXP) quercetin 3-O-beta-D-glucopyranoside (EXP) sinigrin (EXP) sodium arsenite (ISO) sodium dichromate (EXP) streptozocin (EXP) succinic semialdehyde (EXP) Sunset Yellow FCF (ISO) tartrazine (ISO) tetrachloromethane (EXP) thioacetamide (EXP) toluene (EXP) topotecan (EXP) triadimefon (EXP) trichloroethene (EXP) triclosan (ISO) triphenyl phosphate (EXP,ISO) trovafloxacin (EXP) umbelliferone (ISO) valdecoxib (EXP) valproic acid (EXP)
1.
Characterization of the rat aflatoxin B1 aldehyde reductase gene, AKR7A1. Structure and chromosomal localization of AKR7A1 as well as identification of antioxidant response elements in the gene promoter.
Ellis EM, etal., Carcinogenesis 2003 Apr;24(4):727-37.
2.
An ethoxyquin-inducible aldehyde reductase from rat liver that metabolizes aflatoxin B1 defines a subfamily of aldo-keto reductases.
Ellis EM, etal., Proc Natl Acad Sci U S A 1993 Nov 1;90(21):10350-4.
3.
Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.
Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
4.
Rat ISS GO annotations from GOA human gene data--August 2006
GOA data from the GO Consortium
5.
Novel homodimeric and heterodimeric rat gamma-hydroxybutyrate synthases that associate with the Golgi apparatus define a distinct subclass of aldo-keto reductase 7 family proteins.
Kelly VP, etal., Biochem J 2002 Sep 15;366(Pt 3):847-61.
6.
cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3.
Knight LP, etal., Carcinogenesis. 1999 Jul;20(7):1215-23. doi: 10.1093/carcin/20.7.1215.
7.
The crystal structure of rat liver AKR7A1. A dimeric member of the aldo-keto reductase superfamily.
Kozma E, etal., J Biol Chem 2002 May 3;277(18):16285-93. Epub 2002 Feb 11.
8.
GOA pipeline
RGD automated data pipeline
9.
Data Import for Chemical-Gene Interactions
RGD automated import pipeline for gene-chemical interactions
Akr7a3 Rat Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl GRCr8 5 156,876,721 - 156,884,599 (+) NCBI GRCr8 mRatBN7.2 5 151,590,968 - 151,601,394 (+) NCBI mRatBN7.2 mRatBN7.2 mRatBN7.2 Ensembl 5 151,584,479 - 151,601,394 (+) Ensembl mRatBN7.2 Ensembl UTH_Rnor_SHR_Utx 5 154,292,151 - 154,300,047 (+) NCBI Rnor_SHR UTH_Rnor_SHR_Utx UTH_Rnor_SHRSP_BbbUtx_1.0 5 156,066,511 - 156,074,407 (+) NCBI Rnor_SHRSP UTH_Rnor_SHRSP_BbbUtx_1.0 UTH_Rnor_WKY_Bbb_1.0 5 156,047,478 - 156,055,349 (+) NCBI Rnor_WKY UTH_Rnor_WKY_Bbb_1.0 Rnor_6.0 5 157,801,120 - 157,813,756 (+) NCBI Rnor6.0 Rnor_6.0 rn6 Rnor6.0 Rnor_6.0 Ensembl 5 157,801,163 - 157,813,756 (+) Ensembl Rnor6.0 rn6 Rnor6.0 Rnor_5.0 5 161,540,977 - 161,553,468 (+) NCBI Rnor5.0 Rnor_5.0 rn5 Rnor5.0 RGSC_v3.4 5 158,139,986 - 158,147,516 (+) NCBI RGSC3.4 RGSC_v3.4 rn4 RGSC3.4 RGSC_v3.1 5 158,150,024 - 158,157,553 (+) NCBI Celera 5 149,973,124 - 149,980,999 (+) NCBI Celera Cytogenetic Map 5 q36 NCBI
AKR7A3 Human Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl GRCh38 1 19,274,229 - 19,288,770 (-) NCBI GRCh38 GRCh38 hg38 GRCh38 GRCh38.p14 Ensembl 1 19,282,573 - 19,288,770 (-) Ensembl GRCh38 hg38 GRCh38 GRCh37 1 19,609,067 - 19,615,264 (-) NCBI GRCh37 GRCh37 hg19 GRCh37 Build 36 1 19,481,644 - 19,487,867 (-) NCBI NCBI36 Build 36 hg18 NCBI36 Build 34 1 19,354,362 - 19,360,586 NCBI Celera 1 17,936,048 - 17,942,271 (-) NCBI Celera Cytogenetic Map 1 p36.13 NCBI HuRef 1 17,855,438 - 17,861,662 (-) NCBI HuRef CHM1_1 1 19,718,377 - 19,724,602 (-) NCBI CHM1_1 T2T-CHM13v2.0 1 19,097,755 - 19,112,298 (-) NCBI T2T-CHM13v2.0
AKR7A3 Bonobo Assembly Chr Position (strand) Source Genome Browsers JBrowse NCBI UCSC Ensembl NHGRI_mPanPan1-v2 1 207,826,569 - 207,832,727 (+) NCBI NHGRI_mPanPan1-v2 NHGRI_mPanPan1 1 206,941,860 - 206,949,514 (+) NCBI NHGRI_mPanPan1 Mhudiblu_PPA_v0 1 18,241,298 - 18,248,142 (-) NCBI Mhudiblu_PPA_v0 Mhudiblu_PPA_v0 panPan3 PanPan1.1 1 19,287,926 - 19,294,576 (-) NCBI panpan1.1 PanPan1.1 panPan2 PanPan1.1 Ensembl 1 19,288,100 - 19,294,041 (-) Ensembl panpan1.1 panPan2
.
Predicted Target Of
Count of predictions: 45 Count of miRNA genes: 40 Interacting mature miRNAs: 43 Transcripts: ENSRNOT00000024160 Prediction methods: Miranda, Rnahybrid, Targetscan Result types: miRGate_prediction
10053720 Scort26 Serum corticosterone level QTL 26 2.06 0.0147 blood corticosterone amount (VT:0005345) plasma corticosterone level (CMO:0001173) 5 124965598 166875058 Rat 8552960 Pigfal15 Plasma insulin-like growth factor 1 level QTL 15 blood insulin-like growth factor amount (VT:0010479) plasma insulin-like growth factor 1 level (CMO:0001299) 5 111416838 156416838 Rat 2302369 Scl60 Serum cholesterol level QTL 60 3.13 blood cholesterol amount (VT:0000180) serum total cholesterol level (CMO:0000363) 5 143608201 161165651 Rat 631562 Apr2 Acute phase response QTL 2 3.7 blood murinoglobulin 1 amount (VT:0010597) plasma murinoglobulin 1 level (CMO:0001931) 5 135927956 166875058 Rat 61444 Strs2 Sensitivity to stroke QTL 2 4.7 cerebrum integrity trait (VT:0010549) post-insult time to onset of cerebrovascular lesion (CMO:0002343) 5 135929696 166875058 Rat 1300119 Bp180 Blood pressure QTL 180 3.82 arterial blood pressure trait (VT:2000000) blood pressure time series experimental set point of the baroreceptor response (CMO:0002593) 5 144358090 157869054 Rat 8552908 Pigfal4 Plasma insulin-like growth factor 1 level QTL 4 6.6 blood insulin-like growth factor amount (VT:0010479) plasma insulin-like growth factor 1 level (CMO:0001299) 5 128506074 166875058 Rat 61393 Bp7 Blood pressure QTL 7 4.5 0.0001 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 5 60293434 161481680 Rat 7794791 Mcs33 Mammary carcinoma susceptibility QTL 33 1.93 mammary gland integrity trait (VT:0010552) mammary tumor incidence/prevalence measurement (CMO:0000946) 5 131345754 166875058 Rat 7207486 Bss109 Bone structure and strength QTL 109 femur strength trait (VT:0010010) femur total energy absorbed before break (CMO:0001677) 5 106906205 151906205 Rat 1354631 Swd2 Spike wave discharge measurement QTL 2 3.64 0.0002 brain electrophysiology trait (VT:0010557) brain total spike-and-wave discharge duration (CMO:0001740) 5 151113452 164465185 Rat 7207481 Bss106 Bone structure and strength QTL 106 7.9 femur strength trait (VT:0010010) femur ultimate force (CMO:0001675) 5 106906205 151906205 Rat 1302790 Scl20 Serum cholesterol level QTL 20 6.4 0.0001 blood cholesterol amount (VT:0000180) plasma total cholesterol level (CMO:0000585) 5 82394392 166664054 Rat 1598861 Cm64 Cardiac mass QTL 64 2.9 heart mass (VT:0007028) heart weight to body weight ratio (CMO:0000074) 5 127798274 166875058 Rat 1578766 Tcas11 Tongue tumor susceptibility QTL 11 4.12 tongue integrity trait (VT:0010553) number of squamous cell tumors of the tongue with diameter greater than 3 mm (CMO:0001950) 5 46711509 161317411 Rat 631263 Cm24 Cardiac mass QTL 24 3.5 heart mass (VT:0007028) heart left ventricle weight to body weight ratio (CMO:0000530) 5 143799107 158428037 Rat 631505 Bp103 Blood pressure QTL 103 3.2 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 5 132717196 165560427 Rat 1549838 Bss4 Bone structure and strength QTL 4 9.2 femur strength trait (VT:0010010) femur midshaft polar moment of inertia (CMO:0001669) 5 106906205 151906205 Rat 1641920 Colcs1 Colorectal carcinoma susceptibility QTL 1 2.99 0.0055 intestine integrity trait (VT:0010554) benign colorectal tumor surface area measurement (CMO:0001799) 5 121846814 166846814 Rat 8694169 Bw148 Body weight QTL 148 5 0.001 body mass (VT:0001259) body weight gain (CMO:0000420) 5 128506074 166875058 Rat 1331721 Bp210 Blood pressure QTL 210 3.413 arterial blood pressure trait (VT:2000000) blood pressure time series experimental set point of the baroreceptor response (CMO:0002593) 5 143069996 166846814 Rat 8657050 Bw146 Body weight QTL 146 19.84 0.001 body mass (VT:0001259) body weight gain (CMO:0000420) 5 108938288 153938288 Rat 631272 Lanf1 Left ventricular atrial natriuretic factor QTL 1 12 heart left ventricle natriuretic peptide A amount (VT:0010596) heart left ventricle natriuretic peptide A level (CMO:0002165) 5 151113452 166875058 Rat 1576314 Eutr1 Estrogen induced uterine response QTL 1 uterus integrity trait (VT:0010575) pyometritis severity score (CMO:0002009) 5 2138965 166875058 Rat 634349 Bp139 Blood pressure QTL 139 0.001 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 5 128924607 166875058 Rat 724525 Bp147 Blood pressure QTL 147 4.3 0.0001 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 5 126424772 166875058 Rat 1598847 Cm62 Cardiac mass QTL 62 3.4 heart mass (VT:0007028) heart weight to body weight ratio (CMO:0000074) 5 108845856 153845856 Rat 738018 Anxrr4 Anxiety related response QTL 4 5.1 exploratory behavior trait (VT:0010471) percentage of entries into a discrete space in an experimental apparatus (CMO:0000961) 5 130130159 166875058 Rat 2313096 Bmd78 Bone mineral density QTL 78 3.1 0.0001 tibia mineral mass (VT:1000283) total volumetric bone mineral density (CMO:0001728) 5 144377876 161317411 Rat 7207488 Bss110 Bone structure and strength QTL 1 8.4 femur strength trait (VT:0010010) femur stiffness (CMO:0001674) 5 106906205 151906205 Rat 8694441 Bw169 Body weight QTL 169 17.61 0.001 retroperitoneal fat pad mass (VT:0010430) retroperitoneal fat pad weight to body weight ratio (CMO:0000635) 5 111416838 156416838 Rat 7207491 Bss112 Bone structure and strength QTL 112 7 femur morphology trait (VT:0000559) femur midshaft cortical cross-sectional area (CMO:0001663) 5 106906205 151906205 Rat 8694389 Bw160 Body weight QTL 160 6.17 0.001 body lean mass (VT:0010483) lean tissue morphological measurement (CMO:0002184) 5 111416838 156416838 Rat 8694198 Abfw3 Abdominal fat weight QTL 3 16.13 0.001 visceral adipose mass (VT:0010063) abdominal fat pad weight to body weight ratio (CMO:0000095) 5 111416838 156416838 Rat 1298090 Bp155 Blood pressure QTL 155 3.8 arterial blood pressure trait (VT:2000000) mean arterial blood pressure (CMO:0000009) 5 151006154 161165494 Rat 1298089 Scl14 Serum cholesterol level QTL 14 5.8 0.0004 blood cholesterol amount (VT:0000180) plasma total cholesterol level (CMO:0000585) 5 108845856 153845856 Rat 1598819 Bp292 Blood pressure QTL 292 4.3 arterial blood pressure trait (VT:2000000) systolic blood pressure (CMO:0000004) 5 127798274 166875058 Rat
BI275071
Rat Assembly Chr Position (strand) Source JBrowse mRatBN7.2 5 151,601,823 - 151,602,057 (+) MAPPER mRatBN7.2 Rnor_6.0 5 157,814,186 - 157,814,419 NCBI Rnor6.0 Rnor_6.0 5 157,807,608 - 157,807,841 NCBI Rnor6.0 Rnor_5.0 5 161,553,898 - 161,554,131 UniSTS Rnor5.0 Rnor_5.0 5 161,547,422 - 161,547,655 UniSTS Rnor5.0 RGSC_v3.4 5 158,147,946 - 158,148,179 UniSTS RGSC3.4 Celera 5 149,981,429 - 149,981,662 UniSTS RH 3.4 Map 5 1044.7 UniSTS Cytogenetic Map 5 q36 UniSTS
AA891811
Rat Assembly Chr Position (strand) Source JBrowse mRatBN7.2 5 151,601,235 - 151,601,336 (+) MAPPER mRatBN7.2 Rnor_6.0 5 157,813,598 - 157,813,698 NCBI Rnor6.0 Rnor_6.0 5 157,807,020 - 157,807,120 NCBI Rnor6.0 Rnor_5.0 5 161,553,310 - 161,553,410 UniSTS Rnor5.0 Rnor_5.0 5 161,546,834 - 161,546,934 UniSTS Rnor5.0 RGSC_v3.4 5 158,147,358 - 158,147,458 UniSTS RGSC3.4 Celera 5 149,980,841 - 149,980,941 UniSTS RH 3.4 Map 5 1047.0 UniSTS Cytogenetic Map 5 q36 UniSTS
Click on a value in the shaded box below the category label to view a detailed expression data table for that system.
alimentary part of gastrointestinal system
9
10
49
113
91
90
59
25
59
6
217
96
93
45
60
31
Too many to show, limit is 500. Download them if you would like to view them all.
Ensembl Acc Id:
ENSRNOT00000024160 ⟹ ENSRNOP00000024160
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source mRatBN7.2 Ensembl 5 151,584,479 - 151,601,394 (+) Ensembl Rnor_6.0 Ensembl 5 157,801,163 - 157,813,756 (+) Ensembl
RefSeq Acc Id:
NM_013215 ⟹ NP_037347
RefSeq Status:
PROVISIONAL
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 5 156,876,721 - 156,884,599 (+) NCBI mRatBN7.2 5 151,593,516 - 151,601,394 (+) NCBI Rnor_6.0 5 157,801,163 - 157,813,756 (+) NCBI Rnor_5.0 5 161,540,977 - 161,553,468 (+) NCBI RGSC_v3.4 5 158,139,986 - 158,147,516 (+) RGD Celera 5 149,973,124 - 149,980,999 (+) RGD
Sequence:
GAATTCGACTGCTGGAACCAACGTCCTCTCTTACCCTCCACCTTCTTCTGCCACCTCTACCACGGTCACCATGTCGCAAGCCCGGCCTGCCACTGTGCTGGGTGCCATGGAGATGGGTCGCCGCATGG
hide sequence
RefSeq Acc Id:
XM_039109345 ⟹ XP_038965273
Type:
CODING
Position:
Rat Assembly Chr Position (strand) Source GRCr8 5 156,876,850 - 156,884,598 (+) NCBI mRatBN7.2 5 151,593,662 - 151,601,393 (+) NCBI
RefSeq Acc Id:
NP_037347 ⟸ NM_013215
- UniProtKB:
Q68FZ3 (UniProtKB/Swiss-Prot), Q5EBB7 (UniProtKB/Swiss-Prot), Q9QX16 (UniProtKB/Swiss-Prot), P38918 (UniProtKB/Swiss-Prot), A6ITL5 (UniProtKB/TrEMBL), A0A8L2QCW7 (UniProtKB/TrEMBL)
- Sequence:
MSQARPATVLGAMEMGRRMDVTSSSASVRAFLQRGHTEIDTAFVYANGQSETILGDLGLGLGRSGCKVKIATKAAPMFGKTLKPADVRFQLETSLKRLQCPRVDLFYLHFPDHGTPIEETLQACHQLH
hide sequence
Ensembl Acc Id:
ENSRNOP00000024160 ⟸ ENSRNOT00000024160
RefSeq Acc Id:
XP_038965273 ⟸ XM_039109345
- Peptide Label:
isoform X1
RGD ID: 13694205 Promoter ID: EPDNEW_R4729 Type: multiple initiation site Name: Akr7a3_1 Description: aldo-keto reductase family 7 member A3 SO ACC ID: SO:0000170 Source: EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/ ) Experiment Methods: Single-end sequencing. Position: Rat Assembly Chr Position (strand) Source Rnor_6.0 5 157,801,154 - 157,801,214 EPDNEW
Date
Current Symbol
Current Name
Previous Symbol
Previous Name
Description
Reference
Status
2016-06-08
Akr7a3
aldo-keto reductase family 7 member A3
Akr7a3
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)
Nomenclature updated to reflect human and mouse nomenclature
1299863 APPROVED
2004-09-10
Akr7a3
aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase)
Afar
aflatoxin B1 aldehyde reductase
Symbol and Name updated
1299863 APPROVED
2003-02-27
Afar
aflatoxin B1 aldehyde reductase
Symbol and Name status set to provisional
70820 PROVISIONAL
Note Type
Note
Reference
gene_expression
expressed in liver
632009
gene_product
belongs to the subfamily of aldo-keto reductases
632009
